BillionToOne, Inc. vs NATERA, INC., two Medical Diagnostics stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Where BLLN and NTRA diverge most: on operating margin, BLLN reads 5.0% and NTRA reads -10.1%; on net margin, BLLN reads 8.6% and NTRA reads -7.1%. The rest of the comparable metrics sit closer together. The bull and bear cases for each are in their full reports below.
| Metric | BLLN | NTRA |
|---|---|---|
| Price | $98.15 | $400.47 |
| Market cap | $5.3B | $57.4B |
| Sector | Medical Diagnostics | Medical Diagnostics |
| Stage | Growth | Growth |
| P/E | 172.2 | — |
| P/B | 9.96 | 31.50 |
| P/S | 14.53 | 21.20 |
| EV/EBITDA | 127.4 | — |
| Revenue growth | +88.5% | +37.8% |
| Gross margin | 70.5% | — |
| Operating margin | 5.0% | -10.1% |
| Net margin | 8.6% | -7.1% |
| Return on equity | 5.9% | -10.6% |
| Return on assets | 4.3% | -7.2% |
| Return on invested capital | 4.6% | -11.1% |
| FCF yield | 0.6% | 0.1% |
| Debt / equity | 0.17 | 0.04 |
| Current ratio | 11.69 | 3.00 |
| Altman Z (solvency) | 7.03 | 5.88 |
| Piotroski F (quality) | 6 / 9 | 5 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.